Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Additional questions

  • If a stability program exists, are there adequate policies, procedures, and study protocols?
  • Are storage areas sized and organized to prevent mix-ups? Is general housekeeping neat and orderly?
  • Do written procedures identify storage time beyond which components, containers, and closures must be reexamined before use?
  • Are all materials handled in such a way to prevent contamination and mix-ups?
  • Are materials spaced to allow for cleaning and inspection?
  • Are rejected components, material, and containers quarantined and clearly marked to prevent their use?

Conclusion

During the course of routine production, and as governed by the quality agreement, the sponsor will perform routine audits to ensure continued compliance. With a solid baseline established during the selection phase, the sponsor can then focus on areas where risk to product quality is highest. By properly selecting, evaluating, and monitoring a third-party supplier, the sponsor can ensure continued compliance over the longterm.

Tim Keutzer* is the director of project management at Cubist Pharmaceuticals, 65 Hayden Ave., Lexington, MA 02421, tel. 781.860.8331, fax 781.860.1131,
. Howard Silver is the manager of GMP compliance at Cubist Pharmaceuticals.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here